Ardakani Rumyar, Jia Lucy, Matthews Elizabeth, Thakur Kiran T
Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA.
Columbia University College of Physicians and Surgeons, New York, NY, USA.
Ther Adv Infect Dis. 2024 Sep 20;11:20499361241274246. doi: 10.1177/20499361241274246. eCollection 2024 Jan-Dec.
There have been several major advances in therapeutic options for the treatment of neurological infections over the past two decades. These advances encompass both the development of new antimicrobial therapies and the repurposing of existing agents for new indications. In addition, advances in our understanding of the host immune response have allowed for the development of new immunomodulatory strategies in the treatment of neurological infections. This review focuses on the key advances in the treatment of neurological infections, including viral, bacterial, fungal, and prion diseases, with a particular focus on immunomodulatory treatment options. This review also highlights the process by which clinicians can request access to therapeutic agents on a compassionate or emergency basis when they may not be commercially available. While many therapeutic advances have been achieved in the past several years, there remains a pressing need for the continued development of additional therapeutic agents in the treatment of neurological infections.
在过去二十年中,神经感染治疗选择取得了几项重大进展。这些进展既包括新抗菌疗法的开发,也包括将现有药物用于新适应症。此外,我们对宿主免疫反应认识的进展使得在神经感染治疗中开发新的免疫调节策略成为可能。本综述重点关注神经感染治疗的关键进展,包括病毒、细菌、真菌和朊病毒疾病,特别关注免疫调节治疗选择。本综述还强调了临床医生在治疗药物可能无法商业化获得时,可通过何种程序在同情或紧急情况下申请获取这些药物。虽然在过去几年中已经取得了许多治疗进展,但在神经感染治疗中持续开发更多治疗药物的需求仍然紧迫。